Slingshot members are tracking this event:
FDA approves new dosage strength of Teva's (TEVA) buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence
Slingshot Insights Explained
Sep 07, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Buprenorphine, Naloxone, Sublingual Tablets, Opioid Addiction